

Participation in the HE Call HORIZON-HLTH-2022-DISEASE-06-04: "Development of new effective therapies for rare diseases"

Dear Sir/Madam

EU-OPENSREEN is a non-profit sustainable European Research Infrastructure on chemical biology (more information available at www.eu-openscreen.eu) and currently assembles a consortium for a successful proposal that can address the above call. Besides a library of more than 100.000 small molecule compounds for high throughput screening, we also collected a library of about 2.500 molecules with known bioactivities for repurposing. Our compound facility efficiently stores and distributes compounds and libraries to our screening laboratories for high throughput testing in biochemical, biophysical and cellular assays. Furthermore, through our partner network we have also access to experienced medicinal chemistry groups that can optimize 'hit' compounds into potent and 'rare disease' selective drug candidates.

We are now looking for European partners which can complement our in vitro target-based and phenotypic screening services as well as our medicinal chemistry expertise for building a consortium that is able to tackle groups of rare diseases. In particular, we are looking for organizations with expertise in:

- Rare disease biology
- Target identification
- *In vivo* disease models
- Preclinical drug development
- Biomarker development
- Clinical studies up to phase II
- Pharmacogenomics, network analysis and artificial intelligence
- Data analytics
- Regulatory affairs and intellectual property rights

I am looking forward to hearing from you. Thank you very much for your consideration and time.

With kind regards,



Wolfgang Fecke
Director General, EU-OPENSREEN ERIC